The incoming CEO of Bayer said the company may sell its animal health division if their goal of strategically growing it does not pan out, according to Reuters.
"Should we not succeed at that in the end, we will have to ask the strategic question, as is the case with all our businesses, are these businesses well placed with us as best owner or can these businesses perhaps progress better in a different environment, with different access to resources?" said Strategy Chief Werner Baumann during a media briefing, according to Reuters.
Baumann takes over as CEO on May 1.
According to Reuters, the animal health unit saw a revenue increase of 13% to $1.7 billion last year.
But the company doesn't have a set timeline either.
Baumann said that Bayer has a number of interesting animal health products in the works, including developing drugs to boost farm animals' immune systems, and flea and tick collars for dogs.
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
